Jaguar Health, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2026 am IST			5-day change	1st Jan Change
1.300 ^USD	-2.62%		-43.72%	-96.01%

25/06	Jaguar Health, Inc., Napo Pharmaceuticals, Inc., And Woodward Specialty LLC Amend Manufacturing And Supply Agreement	CI
24/06	Jaguar Health Initiates Strategic-Alternatives Review Ahead of Crofelemer NDA Filing for Rare Intestinal Failure Program	CI

Published on 04/10/2026 at 07:20 pm IST - Modified on 04/15/2026 at 08:27 am IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Greetings, and welcome to Jaguar Health Investor Webcast. [Operator Instructions]

Before I turn the call over to

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

25/06	Jaguar Health, Inc., Napo Pharmaceuticals, Inc., And Woodward Specialty LLC Amend Manufacturing And Supply Agreement	CI
24/06	Jaguar Health Initiates Strategic-Alternatives Review Ahead of Crofelemer NDA Filing for Rare Intestinal Failure Program	CI
23/06	Jaguar Health Files New Animal Drug Application For Full FDA Approval Of Canine Diarrhea Therapy	MT
22/06	Jaguar Health Explores Strategic Alternatives	MT
09/06	Jaguar Health, Inc. announced that it expects to receive $41.99992 million in funding	CI
26/05	Jaguar Health, Inc., Q1 2026 Earnings Call, May 26, 2026
21/05	Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
10/04	Jaguar Health, Inc., Q4 2025 Earnings Call, Apr 10, 2026
07/04	Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
07/04	Jaguar Health, Inc. Auditor Raises 'Going Concern' Doubt	CI
18/02	Jaguar Health to Pay Special Stock Dividend	MT
16/01	Jaguar Health Inc - Co & unit entered license agreement with Woodward Specialty LLC - SEC filing	RE
06/01	Jaguar Health, Inc. announced that it has received $0.35 million in funding	CI
24/11	Jaguar Health, Inc. announced that it has received $10.81 million in funding	CI
21/11	Jaguar Health's Napo Pharmaceuticals Submits Amended Crofelemer Trial Protocol to FDA	MT